Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 2568

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 2568
---
 and Exchange
Commission (the “SEC”) on January 31, 2023 (the “IPO Registration Statement”) and the final prospectus filed
with the SEC pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended. The Registration Statement was declared effective
by the SEC on July 11, 2023. The common stock and tradeable warrants began trading on The Nasdaq Capital Market on July 12, 2023 under
the symbols “SXTP” and “SXTPW,” respectively. The closing of the IPO occurred on July 14, 2023.

Risks and Uncertainties

The Company is subject to risks common to companies
in the biopharmaceutical industry including, but not limited to, the risks associated with developing product candidates and successfully
launching and commercializing its drug/device combination products, the Company’s ability to obtain regulatory approval of its
such products in the United States and other geography markets, the uncertainty of the broad adoption of its approved products by physicians
and consumers, and significant competition.

F-8

In addition, higher rates of inflation have resulted
in the U.S. Federal Reserve raising interest rates. Increases in interest rates, especially if coupled with reduced government spending
and volatility in financial markets, may further increase economic uncertainty and heighten these risks. Furthermore, if additional banks
and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking
system and financial markets, the Company or its partners’ ability to access existing cash, cash equivalents and investments may
be threatened and could have a material adverse effect on the Company’s business and financial condition, including the Company’s
ability to access additional capital on favorable terms, or at all, which could in the future negatively affect the Company’s ability
to pursue its business strategy. 

Going Concern

The Company’s future results are subject to substantial risks
and uncertainties. Since its inception, the Company has not demonstrated the ability to generate enough revenues to date to cover operating
expenses and has accumulated losses to date. At December 31, 2024, the Company had cash and cash equivalents totaling $1,659,353, as compared
to cash and cash equivalents totaling $2,142,485 at December 31, 2023. During the year ended December 31, 2024, the Company used cash
of $5,648,088 in its operating activities ($4,542,